An in-depth discussion featuring the Founder and Editor of Endpoints News, John Carroll, and the Executive VP, Head of Genentech Research & Early Development (gRED) at Genentech, Aviv Regev.

An in-depth conversation featuring Endpoints Executive Editor Drew Armstrong and Jami Rubin, the Chief Financial Officer at Boundless Bio (and a famed former investment analyst at Goldman Sachs), covering the recent Boundless IPO and Jami’s long career in the biopharma industry.

Endpoints senior biopharma correspondent Andy Dunn talks with Tom Klima, Chief Commercial & Operating Officer at bluebird bio, about lessons learned from being one of the earliest gene therapy companies.

The first round of gene therapies have left the lab and secured FDA approval, but some of the companies that were first out the gate are struggling. What have we learned about creating viable and scalable gene therapies, and what are the lessons to take away from ‘generation 0’?

IPOs are back and biopharmas are raising money. Q1 was marked by signs of life from the market, and the outlook is optimistic. Who came out on top in the bounceback — and who was left behind?

In the dynamic landscape of the pharmaceutical industry, partnerships play a pivotal role in driving innovation, accessing new markets, and enhancing competitive advantage. While big pharma acquisitions often dominate the headlines, mid-size pharmaceutical companies such as Ipsen offer a unique value proposition in collaborations. In this panel we will discuss where mid-size pharma are playing their strengths to secure deals that could dominate future innovations and how their size could offer an advantage to potential partners.

An in-depth conversation featuring Endpoints Executive Editor Drew Armstrong and CEO of Roivant Sciences, Matt Gline.

Chinese manufacturing is squarely in the crosshairs of US regulators, and regardless of whether legislation advances, the relationship between US and Chinese companies has already been changed, likely for good. Our panel explores the latest policy development and how drug developers are grappling with the fast-changing landscape.